Scientists are now checking to see if purified blood serum from people who have recovered from COVID-19 might be more than a useful treatment. Perhaps it's a way to prevent disease in someone else.

Two new human studies back earlier hints that vaccines designed to prevent respiratory infections might also provide some protection against Alzheimer's disease.

Gene therapy has helped a 9-year-old boy regain enough muscle strength to run. If successful in others, the treatment could change the lives of thousands of children with Duchenne muscular dystrophy.

Recent studies have raised fears that immunity to the coronavirus might be fleeting, thus making potential vaccines ineffective. The reality of the science is more complex — and more reassuring.

The first gene therapy for hemophilia could be approved by the FDA within six months, according to the drugmaker, raising hopes among families. But the drug's price could be $3 million per patient.

Faced with a glut of pandemic research from around the world, scientists are confronting their biases and learning to engage with science conducted at institutions they're unfamiliar with.

When scientists revved up the production of an enzyme called GPLD1 in older mice, it stimulated nerve growth in their brains and the animals navigated a maze better.

Structures inside healthy brain cells nimbly move from one state to the next to perform different functions. But in certain degenerative brain diseases, scientists now think, that process gets stuck.

Since receiving a landmark treatment with the gene-editing tool CRISPR, a sickle cell patient has the strength to care for herself and her children — while navigating the pandemic.